share_log

藥明康德：根據2022年H股獎勵信託計劃進一步授予獎勵

WUXI APPTEC: FURTHER GRANT OF AWARDS UNDER THE 2022 H SHARE AWARD AND TRUST SCHEME

香港交易所 ·  Jan 11 04:14
Summary by Moomoo AI
無錫藥明康德於2024年1月11日宣布，根據2022年H股獎勵信託計劃，已向14名獨立選定參與者進一步授予73,389股H股，佔已發行H股總數約0.018%及已發行總股本約0.002%。該批獎勵股份由受託人按公司指示透過市場交易購得，不會對現有股東股權造成攤薄。授予條件包括本集團2022年全年收入同比增長不低於68%，該條件已達成。獎勵股份的歸屬安排分為四個階段，從選定參與者受僱於集團相關成員公司之日起計算。董事會認為此次授予符合公司及股東整體利益。
無錫藥明康德於2024年1月11日宣布，根據2022年H股獎勵信託計劃，已向14名獨立選定參與者進一步授予73,389股H股，佔已發行H股總數約0.018%及已發行總股本約0.002%。該批獎勵股份由受託人按公司指示透過市場交易購得，不會對現有股東股權造成攤薄。授予條件包括本集團2022年全年收入同比增長不低於68%，該條件已達成。獎勵股份的歸屬安排分為四個階段，從選定參與者受僱於集團相關成員公司之日起計算。董事會認為此次授予符合公司及股東整體利益。
Wuxi Pharmaceutical Ming Kand announced on 11 January 2024 that it has further granted 73,389 shares of H shares to 14 independently selected participants under the H Share Award Trust Scheme 2022, representing approximately 0.018% of the total number of H shares issued and approximately 0.002% of the total issued share capital. This batch of bonus shares was purchased by the Trustee through market transactions as directed by the Company and will not cause dilution to existing shareholders' equity. The award conditions include the Group's full-year revenue growth of no less than 68% in 2022, which has been met. The allocation arrangement of the bonus shares is divided into four stages, calculated from the date on which the selected participant is employed by the relevant member company of the group. The Board considers that this award is in the overall interests of the Company and its shareholders.
Wuxi Pharmaceutical Ming Kand announced on 11 January 2024 that it has further granted 73,389 shares of H shares to 14 independently selected participants under the H Share Award Trust Scheme 2022, representing approximately 0.018% of the total number of H shares issued and approximately 0.002% of the total issued share capital. This batch of bonus shares was purchased by the Trustee through market transactions as directed by the Company and will not cause dilution to existing shareholders' equity. The award conditions include the Group's full-year revenue growth of no less than 68% in 2022, which has been met. The allocation arrangement of the bonus shares is divided into four stages, calculated from the date on which the selected participant is employed by the relevant member company of the group. The Board considers that this award is in the overall interests of the Company and its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more